Compare Southwest Airlines Co (LUV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs State Street SPDR S&P Biotech ETF — how do they compare? Southwest Airlines Co trades at $45.02 (market cap $22.27B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Southwest Airlines Co pays a 1.58% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Southwest Airlines Co nearer its low. Which is the better fit depends on your goals.
| LUV | XBI | |
|---|---|---|
Market Cap | $22.27B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $54.80 | $164.28 |
52-Week Low | $29.67 | $86.92 |
Enterprise Value | $25.37B | — |
Dividend Yield | 1.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $45.06, up 0.36% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings with $0.94 EPS beating expectations by 84%, while Q1 missed estimates. Revenue growth continues with 2026 projections at $30.1B, though net margins remain thin at 2.78%. Recent board appointments and business travel initiatives signal strategic focus on premium segments.
LUV presents a value opportunity with attractive P/S (0.79) and dividend yield, but faces headwinds from fuel cost volatility and competitive pressures. Analyst consensus targets $53.86 (20% upside) with mixed ratings. The stock's outlook hinges on sustained travel demand and effective cost management amid industry challenges.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
